ROLUL TERAPIEI DE ACTIVARE BAROREFLEXĂ LA PACIENȚII CU HIPERTENSIUNE REZISTENTĂ

Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Himmelfarb CD, et al. Clinical Practice Guideline 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults A Report of the American College of Cardiology. 2018. 13–115 p.

Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–104.

Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117(25):e510–26

Persell SD. Prevalence of resistant hypertension in the United States, 2003–2008. Hypertens (Dallas, Tex 1979). 2011;57(6):1076–80.

Achelrod D, Wenzel U, Frey S. Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations. Am J Hypertens. 2015;28(3):355–61.

Kass JS, Mizrahi EM. Neurology secrets e-book. Elsevier Health Sciences; 2010 Apr 30.Available from: https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/baroreceptor (accessed 26.2.2021

Kenhub STN Available from: https://www.kenhub.com/en/library/anatomy/the-solitary-tract-and-nucleus (accessed 26.2.2021

Armstrong M, Moore RA. Physiology, Baroreceptors. StatPearls [Internet]. 2020 Mar 23.Available from:https://www.statpearls.com/articlelibrary/viewarticle/18138/ (accessed 26.2.2021)

Fig 1Această figură a fost creată folosind șabloane Servier Medical Art, care sunt licențiate sub o licență Creative Commons Attribution 3.0 Unported. Fig .2 https://link.springer.com/article/10.1007/s11906-020-1024-x/figures/2

Kougias P, Weakley SM, Yao Q, Lin PH, Chen C. Arterial baroreceptors in the management of systemic hypertension. Med Sci Monit. 2010;16(1):RA1–8.

Tordoir JHM, Scheffers I, Schmidli J, Savolainen H, Liebeskind U, Hansky B, et al. An implantable carotid sinus baroreflex activating system: surgical technique and short-term outcome from a multi-center feasibility trial for the treatment of resistant hypertension. Eur J Vasc Endovasc Surg. 2007;33(4):414–21

Lohmeier TE, Irwin ED, Rossing MA, Serdar DJ, Kieval RS. Prolonged activation of the baroreflex produces sustained hypotension. Hypertens (Dallas, Tex 1979). 2004;43(2):306–11.

Illig KA, Levy M, Sanchez L, Trachiotis GD, Shanley C, Irwin E, et al. An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter phase II Rheos feasibility trial. J Vasc Surg. 2006;44(6):1213–8

Scheffers IJM, Kroon AA, Schmidli J, Jordan J, Tordoir JJM, Mohaupt MG, et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol. 2010;56(15):1254–8.

Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol. 2011;58(7):765–73.

Bakris GL, Nadim MK, Haller H, Lovett EG, Schafer JE, Bisognano JD. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens. 2012;6(2):152–8.

de Leeuw PW, Bisognano JD, Bakris GL, Nadim MK, Haller H, Kroon AA. Sustained Reduction of Blood Pressure With Baroreceptor Activation Therapy: Results of the 6-Year Open Follow-Up. Hypertens (Dallas, Tex 1979). 2017 May;69(5):836–43. A combined long-term follow-up study of the US Rheos Feasibility Trial, the DEBuT-HT Trial and the Rheos Pivotal Trial showed sustained effect on blood pressure after 6 years of follow-up.

Hoppe UC, Brandt M-C, Wachter R, Beige J, Rump LC, Kroon AA, et al. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens. 2012;6(4):270–6

Wallbach M, Lehnig L-Y, Schroer C, Luders S, Bohning E, Muller GA, et al. Effects of baroreflex activation therapy on ambulatory blood pressure in patients with resistant hypertension. Hypertens (Dallas, Tex 1979). 2016;67(4):701–9

Heusser K, Tank J, Brinkmann J, Menne J, Kaufeld J, Linnenweber-Held S, et al. Acute response to unilateral unipolar electrical carotid sinus stimulation in patients with resistant arterial hypertension. Hypertens (Dallas, Tex 1979). 2016;67(3):585–91.

Halbach M, Hickethier T, Madershahian N, Reuter H, Brandt MC, Hoppe UC, et al. Acute on/off effects and chronic blood pressure reduction after long-term baroreflex activation therapy in resistant hypertension. J Hypertens. 2015;33(8):1697–703.

Wallbach M, Born E, Kampfer D, Luders S, Muller GA, Wachter R, et al. Long-term effects of baroreflex activation therapy: 2-year follow-up data of the BAT neo system. Clin Res Cardiol. 2019.

Wallbach M, Lehnig L-Y, Schroer C, Hasenfuss G, Muller GA, Wachter R, et al. Impact of baroreflex activation therapy on renal function--a pilot study. Am J Nephrol. 2014;40(4):371–80.

Beige J, Koziolek MJ, Hennig G, Hamza A, Wendt R, Muller GA, et al. Baroreflex activation therapy in patients with end-stage renal failure: proof of concept. J Hypertens. 2015;33(11):2344–9.

Gronda E, Seravalle G, Brambilla G, Costantino G, Casini A, Alsheraei A, et al. Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: a proof-ofconcept study. Eur J Heart Fail. 2014;16(9):977–83

Abraham WT, Zile MR, Weaver FA, Butter C, Ducharme A, Halbach M, et al. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction. JACC Heart Fail. 2015;3(6):487–96

Weaver FA, Abraham WT, Little WC, Butter C, Ducharme A, Halbach M, et al. Surgical experience and long-term results of baroreflex activation therapy for heart failure with reduced ejection fraction. Semin Thorac Cardiovasc Surg. 2016;28(2):320–8.

Zile MR, Abraham WT, Lindenfeld J, Weaver FA, Zannad F, Graves T, et al. First granted example of novel FDA trial design under expedited access pathway for premarket approval: BeAT-HF. Am Heart J. 2018;204:139–50

Zile M, Lindenfeld J, Weaver FA, Zannad F, Galle E, Rogers T, et al. Baroreflex activation therapy (bat) in patients with heart failure and a reduced ejection fraction (HFrEF): The BeAT-HF Trial. Available SSRN 3452105. 2019; The first successful phase III pivotal trial of baroreflex amplification via the Barostim neo in HFrEF patients.